Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

Kucukyurt S., Yagiz Ozogul Y., Ercaliskan A., Kabasakal L., Eskazan A. E.

CANCER REPORTS, cilt.3, sa.5, 2020 (ESCI, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 3 Sayı: 5
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1002/cnr2.1282
  • Dergi Adı: CANCER REPORTS
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Anahtar Kelimeler: chronic myeloid leukemia, neuroendocrine tumor, peptide receptor radionuclide therapy, therapy-related leukemia, tyrosine kinase inhibitor, MYELODYSPLASTIC SYNDROME, TYROSINE KINASE
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Background Therapy-related leukemia is a well-recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors. Aims Hematologic toxicities including late-onset myeloid neoplasms have been reported after PRRT; however, therapy-related chronic myeloid leukemia (TR-CML) following PRRT is a relatively rare entity. Methods We present a 64-year-old male who received PRRT for pancreas neuroendocrine tumor and then developed TR-CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy. Results Patients with TR-CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases. Conclusions The physicians should be aware of the short- and long-term hematologic toxicities of PRRT including TR-CML, and careful monitoring is mandatory in this group of patients.